Overview
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
Status:
Completed
Completed
Trial end date:
2008-06-01
2008-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety and efficacy of ONO-2333Ms in patients with Recurrent Major Depressive DisorderPhase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Ono Pharma USA Inc
Criteria
Inclusion Criteria:- Diagnosed with recurrent major depressive disorder
Exclusion Criteria:
- Patients with treatment resistance for depression
- History of alcohol abuse/dependence, substance abuse/dependence within 6 months
- Has clinically significant unstable medical condition
- Has significant risk of suicide